<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Bone marrow transplantation, used in the treatment of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, and <z:e sem="disease" ids="C0025517" disease_type="Disease or Syndrome" abbrv="">metabolic diseases</z:e>, involves the use of potentially <z:chebi fb="0" ids="50910">neurotoxic agents</z:chebi> to suppress immunity and eradicate <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Fifty-seven patients with a median age of 11 years (age range, 6 months to 24 years) underwent bone marrow transplantation at the Children's Hospital of Philadelphia </plain></SENT>
<SENT sid="2" pm="."><plain>Fifty-nine percent developed <z:hpo ids='HP_0000707'>neurological abnormalities</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Twenty-six patients (46%) had central <z:mp ids='MP_0008912'>nervous</z:mp> system (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>) dysfunction, including <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> (8), <z:hpo ids='HP_0001297'>cerebrovascular accident</z:hpo> (5), <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> <z:hpo ids='HP_0001909'>leukemia</z:hpo> (7), metabolic <z:hpo ids='HP_0001298'>encephalopathy</z:hpo> (5), and <z:hpo ids='HP_0002385'>paraparesis</z:hpo> with <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> <z:e sem="disease" ids="C0040558" disease_type="Disease or Syndrome" abbrv="">toxoplasmosis</z:e> (1) </plain></SENT>
<SENT sid="4" pm="."><plain>Neuropsychological dysfunction was present in 4 of 5 long-term survivors who were tested </plain></SENT>
<SENT sid="5" pm="."><plain>Fourteen of 19 patients (74%) on whom postmortem examination was performed were found to have <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> abnormalities, including <z:hpo ids='HP_0002059'>cerebral atrophy</z:hpo> (10), focal cerebral injury (6), <z:hpo ids='HP_0001909'>leukemia</z:hpo> (5), and <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> (3) </plain></SENT>
<SENT sid="6" pm="."><plain>Fourteen patients (24%) had peripheral <z:mp ids='MP_0008912'>nervous</z:mp> system dysfunction </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> dysfunction was more common in patients with lymphoreticular <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0001297'>Cerebrovascular accidents</z:hpo> (in patients with lymphoreticular <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>) and <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> (in our general population and in patients with lymphoreticular <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>) occurred more often in our patients than in patients with similar illnesses who did not undergo bone marrow transplantation </plain></SENT>
<SENT sid="9" pm="."><plain>The combination of prior treatment and preparative therapy for bone marrow transplantation predisposes patients to neurological and neuropsychological sequelae </plain></SENT>
</text></document>